# Junta clínica — PT-pseudo_c13fda040310 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c13fda040310",
  "pid": "PT-pseudo_c13fda040310",
  "task": 1,
  "psa": 6.1,
  "age": 63,
  "months": 3,
  "pirads": "4",
  "psad": 0.08,
  "psav": 1.35,
  "psap": 4.9,
  "vol": 73.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.81674135,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin",
  "notes": "PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "81 kg",
    "height": "180 cm",
    "bmi": "25.0",
    "bp": "125/95 mmHg",
    "hr": "72 bpm",
    "smoking": "Current smoker (23 pack-yr)",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation."
    },
    {
      "s": "History",
      "t": "Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses."
    }
  ],
  "occupation": "freelance translator",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [],
  "alcohol": "1 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 5/35 (mild LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "Catharina Ziekenhuis (Eindhoven)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c13fda040310
Task: 1

Encounter: Urology - outpatient on 19 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.35 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81674135 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.

Vitals: weight 81 kg, height 180 cm, BMI 25.0, BP 125/95 mmHg, HR 72 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation.

History: Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses.

Patient info: freelance translator; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 5x/week (commuter); IPSS score: 5/35 (mild LUTS).


Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.10 epistemic (95% band 0.62-1.00); among patients I cannot tell apart the outcome was 0.68 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Negative (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 4 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 63 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 6.1 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 73 mL (1% of my signal; from log_vol, vol) · PSA density = 0.08 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.82 (1% of my signal; from cspca) · PI-RADS = 4 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers BIOPSY.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 4
  important  prior biopsy = Negative
  noted      age = 63 · DRE = Normal · PSA = 6.1 ng/mL · prostate volume = 73 mL · PSA density = 0.08 · comorbidity = 4 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: borderline — the rule matched the reading urologist in 16 of 18 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 17 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.59: PI-RADS 4, PSA 6.0, PSAD 0.08, age 67, DRE Normal -> BIOPSY (clear). He wrote: "P4 lesion in 67 year old patient."
  2. distance 1.58: PI-RADS 4, PSA 9.2, PSAD 0.16, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Again earlier MRI report is missing, If new PRADS 4 lesion biopsy is needed as PSA is rising as well"
  3. distance 1.62: PI-RADS 4, PSA 3.0, PSAD 0.12, age 68, DRE Normal -> BIOPSY (borderline). He wrote: "PIRADS 4 lesion in 68 year old man with heavy comorbidity. Earlier negative biopsy."

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is fair here (0.78 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 4
  important  prior biopsy = Negative · comorbidity = 4 on the problem list
  noted      family history = not opened (0 of 91) · age = 63 · DRE = Normal · PSA = 6.1 ng/mL · prostate volume = 73 mL
  not used   PSA density, csPCa probability
CONFIDENCE: borderline — the library is right 78% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 17 labelled traces in this situation (Negative prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Negative · age = 63 · PSA = 6.1 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 73 mL · PSA density = 0.08 · comorbidity = 4 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy after a negative systematic biopsy should be considered dependent on risk factors such as PSA density, PSA velocity, and PI-RADS score. The guideline suggests that low PSA-D (< 0.15 ng/mL/cc) and low PSA velocity (PSAV) may be factors to exclude a repeat biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that it marked prior biopsy as decisive, whereas the guideline treats this as context. The guideline suggests that low PSA-D and PSA velocity may be factors to exclude a repeat biopsy, which is a variable the guideline makes decisive for this situation. The guideline requires a comparison MRI or a due confirmatory biopsy to be established, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the note regarding the patient's apprehension about another invasive procedure: at this, the guideline suggests that risk factors like low PSA-D and PSA velocity should be considered to individualise the need for a repeat biopsy.
radiology_report - the MRI report must be compared against an earlier study: if the MRI shows a PI-RADS 4-5 lesion, the guideline suggests a repeat biopsy to confirm histological progression.
psa_trend - the PSA trend must be compared against an earlier study: if the PSA velocity is low, the guideline suggests this factor should be considered when deciding on a repeat biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the low PSA density and PSA velocity, as per the EAU guideline, are sufficient to exclude a repeat biopsy despite the PI-RADS 4 finding.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Must show if the MRI shows a PI-RADS 4-5 lesion that requires a repeat biopsy.
  psa_trend (get_psa_trend) -> Must show if the PSA velocity is low, as this factor should be considered when deciding on a repeat biopsy.
  previous_notes (get_previous_notes) -> Must address the patient's apprehension regarding another invasive procedure in light of the guideline's suggestion.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What should be done given the low PSA density and PSA velocity?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the radiology_report show a PI-RADS 4-5 lesion that requires a repeat biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The MRI report shows a focal lesion (approximately 12 x 9 x 11 mm) in the left mid-gland posterior peripheral zone demonstrating restricted diffusion and early contrast enhancement.
psa_trend
The PSA velocity is not low, as the trend shows a significant rise from 1.4 ng/mL in Jun 2023 to 6.1 ng/mL in Feb 2025.
previous_notes
The previous notes address the patient's apprehension, noting that a systematic biopsy in June 2024 returned entirely benign results.

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI report shows a PI-RADS 4 lesion, which aligns with the cohort criterion for repeat biopsy.
The PSA trend shows a significant rise, indicating an active trajectory that warrants further investigation.
AGAINST sampling this patient now
The previous notes confirm that a systematic biopsy was previously performed and was negative.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.10 ng/mL over 4 points spanning 20 months; velocity +2.75 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 9.4 ng/mL, conformal 95% band 2.7-32.6.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 6.1 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.81
  uncertainty  +/- 0.09 epistemic (95% band 0.64-0.98), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Negative (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 4 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 6.1 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 73 mL (4% of my signal; from log_vol, vol) · PSA density = 0.08 (0% of my signal; from psad_calc) · comorbidity = 4 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.82  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.81  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_4; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_4) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 16 of 18 labelled cases in exactly this situation (prior negative biopsy).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Negative                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          63                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          6.1 ng/mL                    E1:not E3:not cohort:not library:not E2:not          -> important
  vol          73 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.08                         E1:not E3:not cohort:not library:— E2:—              -> noted
  cspca        0.82                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       4                            E1:not E3:IMP cohort:DEC library:DEC E2:—            -> important
  comorbidity  4 on the problem list        E1:IMP E3:not cohort:not library:IMP E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) have answered the moderator's questions by showing a PI-RADS 4 lesion in the MRI, a non-low PSA velocity, and confirming the prior negative biopsy.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the cohort criterion (PI-RADS $\ge 4$) fired, which is the rule that led to the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What should be done given the low PSA density and PSA velocity? The registrar's report showed the PSA velocity was not low, which mitigates the guideline's suggestion to exclude a repeat biopsy based on that factor.

WHAT CARRIES WEIGHT, AND WHY
<pirads>: important: 4 (The PI-RADS score of 4 was important as it was decisive for the cohort criterion firing, which is the panel's primary justification.)
<psa>: important: 6.1 ng/mL (The PSA level was important as it was noted by multiple experts, reflecting the clinical context.)
<prior biopsy>: decisive: Negative (The prior negative biopsy was decisive as it was a key factor in the cohort criterion matching the reading urologist.)
My confidence in the record as it stands is clear, as the trace model's plan was fully executed.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a repeat biopsy based on the alignment of the cohort criterion and the finding of a PI-RADS 4 lesion, despite the low PSA density and non-low PSA velocity.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

PI-RADS 4 lesion with rising PSA velocity from 1.4 to 6.1 ng/mL warrants repeat targeted biopsy despite prior negative result. Low PSA density of 0.08 supports observation, but the lesion is new and PI-RADS 4 dictates further sampling. No prior biopsy grade was recorded.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
